InflaRx NV Valuation
| IFRX Stock | USD 2.36 0.05 2.16% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. InflaRx NV retains a regular Real Value of $4.44 per share. The prevalent price of the firm is $2.36. Our model calculates the value of InflaRx NV from evaluating the firm fundamentals such as Return On Asset of -0.22, shares owned by insiders of 7.34 %, and Return On Equity of -0.45 as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that InflaRx NV's price fluctuation is unstable at this time. Calculation of the real value of InflaRx NV is based on 3 months time horizon. Increasing InflaRx NV's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since InflaRx NV is currently traded on the exchange, buyers and sellers on that exchange determine the market value of InflaRx Stock. However, InflaRx NV's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.36 | Real 4.44 | Hype 2.39 |
The intrinsic value of InflaRx NV's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence InflaRx NV's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of InflaRx NV helps investors to forecast how InflaRx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of InflaRx NV more accurately as focusing exclusively on InflaRx NV's fundamentals will not take into account other important factors: InflaRx NV Total Value Analysis
InflaRx NV is currently projected to have valuation of 87.78 M with market capitalization of 151 M, debt of 1.12 M, and cash on hands of 23.68 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the InflaRx NV fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
87.78 M | 151 M | 1.12 M | 23.68 M |
InflaRx NV Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. InflaRx NV has an asset utilization ratio of 0.0525 percent. This suggests that the Company is making $5.25E-4 for each dollar of assets. An increasing asset utilization means that InflaRx NV is more efficient with each dollar of assets it utilizes for everyday operations.InflaRx NV Ownership Allocation
InflaRx NV has a total of 58.88 Million outstanding shares. InflaRx NV retains 7.34 (percent) of its outstanding shares held by insiders and 22.52 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.InflaRx NV Profitability Analysis
The company reported the previous year's revenue of 63.09 K. Net Loss for the year was (42.67 M) with profit before overhead, payroll, taxes, and interest of 0.About InflaRx NV Valuation
Our relative valuation model uses a comparative analysis of InflaRx NV. We calculate exposure to InflaRx NV's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of InflaRx NV's related companies.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. Fireman BV is traded on NASDAQ Exchange in the United States.
InflaRx NV Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 54.9 M |
Additional Tools for InflaRx Stock Analysis
When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.